InvestorsHub Logo
Followers 82
Posts 6707
Boards Moderated 0
Alias Born 02/03/2018

Re: eightisenough post# 302297

Wednesday, 09/30/2020 8:02:03 PM

Wednesday, September 30, 2020 8:02:03 PM

Post# of 424477
8- quote:"I urged them to find a way (late amicus brief) to enter Dr. Bhatt's paper before hearing--but management (not JT himself) pushed back and told me they were afraid to focus on Mori too much...????"

Exactly???????

IMHO, the big disqualifier for DU was when she stated, "The USPTO did "NOT" consider Kurabayashi." Singer needs to make a BOLD case of this erroneous claim. The entirety of the patent grants hindged on the unexpected reduction of APO-B. She indicted herself, when she assigned weakness to the unexpected APO-B reduction as something that wasn't considered by the agency, and therefore, "in her eyes" the claim is "weak" at best. In other words, she wholesale eliminated this claim from s.c. altogether in favor of embracing irrelevant obsure studies. Which introduces us to her second disqualifier, when she copy and pasted the defense's statistically false characterization of Kurabayashl.

ILT
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News